London, Feb 3, 2026, 09:29 (GMT) — Regular session.
- Haleon shares slipped roughly 0.5% in early trading, retreating from the day’s peak
- Company issues routine update on treasury stock and voting shares
- Attention now turns to 2025 results and any hints about 2026 demand, particularly in North America
Haleon (HLN) slipped 0.5% to 380.7 pence on Tuesday, down by 2 pence. The share price has fluctuated between 380.15p and 383.30p today, with a market cap near £34 billion. (Investing)
The move may be slight, yet it comes during a lull for the consumer health group, as investors sit tight ahead of the upcoming earnings instead of reacting to the filing.
This is crucial as Haleon’s upcoming update will go beyond just reporting profits. Investors want to know if demand remains steady in the U.S. and if margins can get better without pushing prices too high.
On Monday, a regulatory notice revealed that Haleon had 8,952,353,648 ordinary shares as of Jan. 31, with 45,557,120 held in treasury. That meant 8,906,796,528 shares carried voting rights — the figure used for large-stake disclosures under Financial Conduct Authority rules. (TradingView)
Analyst forecasts on Haleon’s investor site — sourced through Vuma Financial Limited — project organic growth of 3.4% for 2025. (Organic growth excludes currency fluctuations and acquisitions.) The consensus also anticipates a 22.4% adjusted operating margin alongside 18.4 pence in adjusted earnings per share that year. (Haleon Corporate)
Haleon’s lineup covers oral health, vitamins and supplements, pain relief, and respiratory products, among other sectors. Its key brands include Sensodyne, Centrum, and Advil. The company breaks down its performance across North America, EMEA & LatAm, and Asia Pacific. (Reuters)
Investors often see the voting-rights statement as routine. Yet, it offers a quick look at treasury shares—company-held stock without voting power—and, with earnings season near, it refocuses attention on the fundamentals.
But another trigger could still shake the shares. Haleon, spun off from GSK in 2022, downgraded its 2025 organic revenue growth forecast last year, citing a U.S.-driven slowdown. Jefferies Financial Group analysts called it “not a good update,” while CEO Brian McNamara pointed to more unpredictable cold-and-flu demand. (Reuters)
Haleon plans to release its full-year 2025 results on Feb. 25. Following that, the company will provide its first-quarter trading update on April 29. (Haleon Corporate)
